EMEA-001741-PIP04-17-M02 - paediatric investigation plan
upadacitinib
PIPHuman
AbbVie Ltd
E-mail: paediatricteam@abbvie.com
Tel. +44 (0)1628 408248
P/0166/2021: EMA decision of 14 April 2021 on the acceptance of a modification of an agreed paediatric investigation plan for upadacitinib (Rinvoq), (EMEA-001741-PIP04-17-M02)